作者: Zeyu Zhang , Yuanjian Fang , Cameron Lenahan , Sheng Chen
DOI: 10.1016/J.EXPNEUROL.2020.113535
关键词:
摘要: Abstract Aneurysmal subarachnoid hemorrhage (aSAH) is a devastating disease, which mainly caused by the rupture of an intracranial aneurysm. Clinical trials have demonstrated that cerebral vasospasm (CVS) not sole contributor to delayed ischemia (DCI) and poor outcomes in patients with aSAH. Currently, accumulating evidence suggests early brain injury (EBI), occurs within 72 h after onset aSAH, lays foundation for subsequent pathophysiological changes patients. The pathological mechanisms EBI include increased pressure, oxidative stress, neuroinflammation, blood-brain barrier (BBB) disruption, edema cell death. Among them, immune inflammatory responses involve variety cells active substances, play important role aSAH may be related DCI long-term outcomes. Thus, attention should paid strategies targeting responses. In this review, we discuss occurrence development as well some biomarkers CVS, DCI, addition, also summarize potential therapeutic drugs target current research.